Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma.

Literature DB >> 31799208

Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma.

Taigo Hata¹, Tadashi Uwagawa¹, Katsuhiko Yanaga¹.

Abstract

Entities: Chemical Disease

Year: 2019 PMID： 31799208 PMCID： PMC6883475 DOI： 10.1159/000496546

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

5 in total

1. A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.

Authors: Kyle Arneson; Joshua Mondschein; Mark Stavas; Anthony J Cmelak; Albert Attia; Leora Horn; Kenneth Niermann; Igor Puzanov; A Bapsi Chakravarthy; Fen Xia
Journal: J Neurooncol Date: 2017-05-09 Impact factor: 4.130

2. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Authors: Walter M Stadler; Robert A Figlin; David F McDermott; Janice P Dutcher; Jennifer J Knox; Wilson H Miller; John D Hainsworth; Charles A Henderson; Jeffrey R George; Julio Hajdenberg; Tamila L Kindwall-Keller; Marc S Ernstoff; Harry A Drabkin; Brendan D Curti; Luis Chu; Christopher W Ryan; Sebastien J Hotte; Chenghua Xia; Lisa Cupit; Ronald M Bukowski
Journal: Cancer Date: 2010-03-01 Impact factor: 6.860

1 in total

1. Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma.

Authors: Pang-Shuo Perng; Yu-Hsuan Lai; Po-Hsuan Lee; Chi-Chen Huang; Hao-Hsiang Hsu; Jung-Shun Lee
Journal: J Clin Med Date: 2022-03-11 Impact factor: 4.241

1 in total

Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma.

1. A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.

2. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

3. Report of the 19th follow-up survey of primary liver cancer in Japan.

4. What is the risk of intracranial bleeding during anti-VEGF therapy?

5. Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma.

1. Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma.